Clinical Trial: ECOG-ACRIN EA8212

ECOG-ACRIN EA8212

Status: Open

A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Eligible for screening study DCP 001

EA8212 will be closed to accrual, effective  July 24, 2025.